Scientific Evidence - The Clinic of Change

Scientific
Evidence

Partners

Estudo pioneiro quer demonstrar eficácia de psicadélico no tratamento da anorexia

Um estudo levado a cabo pela Shortwave Life Sciences está a avaliar a eficácia da psilocibina no tratamento da anorexia. Esta substância psicadélica de origem natural, proveniente de certos cogumelos.

Ketamine: the psychedelic that revolutionized the treatment of depression

The use of psychedelic drugs has been gaining momentum in the treatment of mental illness. It is mainly ketamine that is used in psychotherapy treatments, but studies seem to point to advantages in the clinical use of psilocybin in the treatment of resistant depression, addictive behaviors, eating disorders and pain management.

FDA clinical trial of psychedelic drug obtains promising new results in the treatment of depression

In this new study, a dose of 12 milligrams of GLP-003 administered eight weeks after an initial dose of 12, 8 or 0.3 milligrams produced additional, rapid and clinically relevant antidepressant effects, which were maintained for up to eight weeks.

Cetamina e escetamina melhoram qualidade de vida de doentes com depressão grave e resistente, aponta estudo

A new study carried out by Canadian experts concludes that the use of ketamine and esketamine in the treatment of severe depression (major depressive disorder) and treatment-resistant depression can lead to a substantial improvement in the quality of life of the respective patients.

ADHD: more than a million new diagnoses in recent years

In the United States, for example, it is estimated that around 1 in 9 children have already received this diagnosis. In Europe too, the number of families seeking specialized assessment has grown significantly. What explains this trend?

Ketamine and the antidepressant revolution: new treatments and innovative mechanisms

The approval of esketamine (Spravato) and brexanolone (Zulresso) in 2019 paved the way for substances such as psilocybin and MDMA, which could be the next to receive regulatory approval.

Ketamine: the biggest revolution in depression treatment in 50 years

The discovery of ketamine's antidepressant potential not only broadened treatment options, but also challenged and renewed the theoretical foundations of psychiatry.

Esketamine: an effective alternative for treating major depression

A case study published in the journal Frontiers in Psychiatry has reinforced the therapeutic potential of intranasal esketamine as a viable alternative in situations of high therapeutic resistance.

Research into Psychedelic-Assisted Psychotherapy highlights the importance of describing therapeutic techniques

The use of psychedelic drugs has been gaining momentum in the treatment of mental illness. It is mainly ketamine that is used in psychotherapy treatments, but studies seem to point to advantages in the clinical use of psilocybin in the treatment of resistant depression, addictive behaviors, eating disorders and pain management.

SCIENTIFIC EVIDENCE

Discover the most relevant international scientific articles on Ketamine-Assisted Psychotherapy.

Ketamine-assisted psychotherapy guarantees long-lasting effects in the treatment of anxiety, depression and post-traumatic stress disorder

A Psicoterapia Assistida por Ketamina garante efeitos duradouros no tratamento de ansiedade, depressão e stress pós-traumático até três e seis meses após o tratamento.

KETAMINE FOR DEPRESSION: Facts, doubts, possibilities, barriers and opportunities

This scientific article, published in JAMA Psychiatry, reinforces the importance of the possibilities offered by Ketamine-Assisted Psychotherapy in the treatment of depression.

PSYCHEDELIC-ASSISTED PSYCHOTHERAPY AND NEUROSCIENCE

A set of studies on the relationship between these two sciences.

THE EFFECT OF KETAMINE ON SLEEP IN THE TREATMENT OF RESISTANT DEPRESSION

Revisão sistemática sobre a forma como a ketamina pode reduzir a gravidade da insónia em pacientes com depressão.

KETAMINE IN THE TREATMENT OF PSYCHIATRIC ILLNESSES AND ADDICTIONS

Presentation of the study published by Cambridge University Press.